GPC3-Targeted Antibody & Cell Therapy

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Format: Word Table
Product Line: Target Pipeline List
Product Code: LMTPL048
Release Date: June of 2019
Category:
Loading...

GPC3-Targeted Antibody & Cell Therapy – Target Pipeline List 06/2019

Targets: Glypican 3; GPC3

This Target Pipeline List provides an overview of GPC3-targeted antibody and cell therapeutics in development for treatment of hepatocellular carcinoma (HCC).

Liver cancer is the second leading cause of cancer-related deaths, and hepatocellular carcinoma is the most common type. Therefore, molecular targets are urgently required for the early detection of HCC and the development of novel therapeutic approaches. Glypican-3 (GPC3), an oncofetal proteoglycan anchored to the cell membrane, is normally detected in the fetal liver but not in the healthy adult liver. However, in HCC patients, GPC3 is overexpressed at both the gene and protein levels, and its expression predicts a poor prognosis.

La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.

The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.

Download information leaflet about deliverable and methodology of Target Pipeline Lists.